{"transactions":[{"id":722558,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-06-30T23:50:38.000Z","date":"2026-06-27","kind":"exercise","planned":true,"acquired":false,"shares":68750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted on June 27, 2024 (the \"Grant Date\") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs were granted on June 27, 2024 (the \"Grant Date\") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."}],"balance_after":137500,"derivative":{"underlying":"Common Stock","underlying_shares":68750},"source":{"system":"sec-edgar","filing":"0001193125-26-291131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526291131/ownership.xml","form_type":"4"}},{"id":722557,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-30T23:50:38.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":30902,"price":13.17,"value":406979.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":87731,"source":{"system":"sec-edgar","filing":"0001193125-26-291131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526291131/ownership.xml","form_type":"4"}},{"id":722556,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-30T23:50:38.000Z","date":"2026-06-27","kind":"exercise","planned":true,"acquired":true,"shares":68750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") converted into one share of the Issuer's Common Stock"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan."}],"balance_after":118633,"source":{"system":"sec-edgar","filing":"0001193125-26-291131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526291131/ownership.xml","form_type":"4"}},{"id":739129,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:02.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526269395/ownership.xml","form_type":"4"}},{"id":942927,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-08T21:05:18.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 6, 2026 (the \"Grant Date\").  The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service."}],"balance_after":700000,"derivative":{"exercise_price":3.81,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001193125-26-007670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000119312526007670/ownership.xml","form_type":"4"}},{"id":1097530,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-07-01T20:37:17.000Z","date":"2025-06-27","kind":"exercise","planned":true,"acquired":false,"shares":68750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted on June 27, 2024 (the \"Grant Date\") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were granted on June 27, 2024 (the \"Grant Date\") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."}],"balance_after":206250,"derivative":{"underlying":"Common Stock","underlying_shares":68750},"source":{"system":"sec-edgar","filing":"0000950170-25-092284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017025092284/ownership.xml","form_type":"4"}},{"id":1097529,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-01T20:37:17.000Z","date":"2025-06-30","kind":"sale","planned":true,"acquired":false,"shares":20618,"price":1.22,"value":25153.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":48132,"source":{"system":"sec-edgar","filing":"0000950170-25-092284","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017025092284/ownership.xml","form_type":"4"}},{"id":1097528,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-01T20:37:17.000Z","date":"2025-06-27","kind":"exercise","planned":true,"acquired":true,"shares":68750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") converted into one share of the Issuer's Common Stock."}],"balance_after":68750,"source":{"system":"sec-edgar","filing":"0000950170-25-092284","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017025092284/ownership.xml","form_type":"4"}},{"id":1112817,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:37:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016971","document":"form4-06122025_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000141588925016971/form4-06122025_080611.xml","form_type":"4"}},{"id":1302263,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-15T21:15:11.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":1150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 13, 2025 (the \"Grant Date\").  The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service."}],"balance_after":1150000,"derivative":{"exercise_price":1.92,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":1150000},"source":{"system":"sec-edgar","filing":"0000950170-25-005840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017025005840/ownership.xml","form_type":"4"}},{"id":1467922,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-06-27T23:05:53.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service."}],"balance_after":275000,"derivative":{"underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000950170-24-078688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017024078688/ownership.xml","form_type":"4"}},{"id":1467921,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T23:05:53.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 27, 2024 (the \"Grant Date\").  The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 27, 2028, subject to the Reporting Person's continued service."}],"balance_after":550000,"derivative":{"exercise_price":7.53,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000950170-24-078688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000095017024078688/ownership.xml","form_type":"4"}},{"id":1476823,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:10:41.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 13, 2024 and will vest in three equal installments on June 13, 2025, June 13, 2026 and June 13, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.05,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-017154","document":"form4-06172024_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714563/000141588924017154/form4-06172024_080637.xml","form_type":"4"}},{"id":1488967,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T00:00:13.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.21,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001415889-24-015854","document":"form4-06062024_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588924015854/form4-06062024_080605.xml","form_type":"4"}},{"id":1741961,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":8666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met."}],"balance_after":8666,"derivative":{"exercise_price":1.85,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":8666},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741960,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":42999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027."}],"balance_after":42999,"derivative":{"exercise_price":1.85,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":42999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741959,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":28943,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026."}],"balance_after":28943,"derivative":{"exercise_price":1.85,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":28943},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741958,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":18999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025."}],"balance_after":18999,"derivative":{"exercise_price":1.85,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":18999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741957,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":12352,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024."}],"balance_after":12352,"derivative":{"exercise_price":1.85,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":12352},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741956,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":12332,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":12332,"derivative":{"exercise_price":1.85,"expiration_date":"2029-03-05","underlying":"Common Stock","underlying_shares":12332},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741955,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":9999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":9999,"derivative":{"exercise_price":1.85,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":9999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741954,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":3600,"derivative":{"exercise_price":1.85,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741953,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":3733,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":3733,"derivative":{"exercise_price":1.85,"expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":3733},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741952,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":5591,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":5591,"derivative":{"exercise_price":1.85,"expiration_date":"2027-05-15","underlying":"Common Stock","underlying_shares":5591},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741951,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met."}],"balance_after":0,"derivative":{"exercise_price":9.3,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":8666},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741950,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":9.3,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":42999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741949,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28943,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026."}],"balance_after":0,"derivative":{"exercise_price":29.25,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":28943},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741948,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":52.5,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":18999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741947,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12352,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024."}],"balance_after":0,"derivative":{"exercise_price":25.5,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":12352},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741946,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12332,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":128.85,"expiration_date":"2029-03-05","underlying":"Common Stock","underlying_shares":12332},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741945,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":118.65,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":9999},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741944,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":143.25,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741943,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3733,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":149.25,"expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":3733},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1741942,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-15T00:23:02.000Z","date":"2023-11-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5591,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the \"Plans\"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":202.95,"expiration_date":"2027-05-15","underlying":"Common Stock","underlying_shares":5591},"source":{"system":"sec-edgar","filing":"0000950170-23-063927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023063927/ownership.xml","form_type":"4"}},{"id":1861289,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T23:55:34.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":12666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":12666,"derivative":{"exercise_price":17.13,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":12666},"source":{"system":"sec-edgar","filing":"0001209191-23-036080","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036080/doc4.xml","form_type":"4"}},{"id":1861288,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:55:34.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":2739,"price":17.52,"value":47987.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":27947,"source":{"system":"sec-edgar","filing":"0001209191-23-036080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036080/doc4.xml","form_type":"4"}},{"id":1861287,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:55:34.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":1994,"price":16.74,"value":33379.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.17 to $17.14. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":30686,"source":{"system":"sec-edgar","filing":"0001209191-23-036080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036080/doc4.xml","form_type":"4"}},{"id":1861286,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:55:34.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":8289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":32680,"source":{"system":"sec-edgar","filing":"0001209191-23-036080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036080/doc4.xml","form_type":"4"}},{"id":1924634,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-04-05T20:15:14.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":19042,"price":0.5758,"value":10964.3836,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person on April 3, 2023 to cover the tax liability in connection with the vesting of three restricted stock awards, vesting on April 1, 2023, that were granted in 2020, 2021, and 2022. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5750 to $0.5798, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":256301,"source":{"system":"sec-edgar","filing":"0000899243-23-010715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924323010715/doc4.xml","form_type":"4"}},{"id":2226085,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T01:08:35.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":25684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":25684,"derivative":{"exercise_price":9,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":25684},"source":{"system":"sec-edgar","filing":"0001209191-22-038603","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038603/doc4.xml","form_type":"4"}},{"id":2226084,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T01:08:35.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":24391,"source":{"system":"sec-edgar","filing":"0001209191-22-038603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038603/doc4.xml","form_type":"4"}},{"id":2302280,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-06T20:39:27.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":8894,"price":2.4459,"value":21753.8346,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person on April 4, 2022 to cover the tax liability in connection with the vesting of two restricted stock awards, vesting on April 1, 2022, that were granted in 2020 and 2021. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.45, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":275343,"source":{"system":"sec-edgar","filing":"0000899243-22-014110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924322014110/doc4.xml","form_type":"4"}},{"id":2407959,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-08T21:05:56.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":434160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on the grant date, which is February 4, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":434160,"derivative":{"exercise_price":1.95,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":434160},"source":{"system":"sec-edgar","filing":"0000899243-22-005213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924322005213/doc4.xml","form_type":"4"}},{"id":2407958,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-02-08T21:05:56.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":106920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted on February 4, 2022, and will vest beginning on April 1, 2022 (the \"Vesting Start Date\") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":284237,"source":{"system":"sec-edgar","filing":"0000899243-22-005213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924322005213/doc4.xml","form_type":"4"}},{"id":2692012,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-28T23:01:07.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":7800,"derivative":{"exercise_price":20.86,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-21-036668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036668/doc4.xml","form_type":"4"}},{"id":2692011,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T23:01:07.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":8614,"source":{"system":"sec-edgar","filing":"0001209191-21-036668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036668/doc4.xml","form_type":"4"}},{"id":2791255,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-12T21:50:41.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":285000,"derivative":{"exercise_price":3.5,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0000899243-21-011334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924321011334/doc4.xml","form_type":"4"}},{"id":2791254,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-12T21:50:41.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":71250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the \"Vesting Start Date\") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":177317,"source":{"system":"sec-edgar","filing":"0000899243-21-011334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924321011334/doc4.xml","form_type":"4"}},{"id":3065150,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-07T23:45:30.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests quarterly over three years from August 5, 2020."}],"balance_after":10400,"derivative":{"exercise_price":42.65,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-20-045766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120045766/doc4.xml","form_type":"4"}},{"id":3065149,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-07T23:45:30.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":6496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":6496,"derivative":{"exercise_price":42.65,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":6496},"source":{"system":"sec-edgar","filing":"0001209191-20-045766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120045766/doc4.xml","form_type":"4"}},{"id":3065148,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-07T23:45:30.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":3914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":3914,"source":{"system":"sec-edgar","filing":"0001209191-20-045766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120045766/doc4.xml","form_type":"4"}},{"id":3183386,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:00:34.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":16.36,"expiration_date":"2028-09-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-20-042761","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042761/a4.xml","form_type":"4"}},{"id":3183385,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:00:34.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":19.88,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-042761","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042761/a4.xml","form_type":"4"}},{"id":3212963,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-12T22:00:12.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":185300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 10, 2020, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":185300,"derivative":{"exercise_price":1.7,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":185300},"source":{"system":"sec-edgar","filing":"0000899243-20-008099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924320008099/doc4.xml","form_type":"4"}},{"id":3212962,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-03-12T22:00:12.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":46300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted on March 10, 2020 (the \"Grant Date\") and will vest in four equal annual installments on each anniversary of the Grant Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date."}],"balance_after":106067,"source":{"system":"sec-edgar","filing":"0000899243-20-008099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924320008099/doc4.xml","form_type":"4"}},{"id":3406180,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-09-25T20:30:20.000Z","date":"2019-09-23","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 23, 2019 (the \"Grant Date\"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date."}],"balance_after":59767,"source":{"system":"sec-edgar","filing":"0000899243-19-024248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924319024248/doc4.xml","form_type":"4"}},{"id":3491267,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-06-13T16:34:17.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 11, 2019, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 11, 2019 or (ii) the Issuer's annual meeting of shareholders in 2020."}],"balance_after":15000,"derivative":{"exercise_price":19.88,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-035363","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465919035363/a4.xml","form_type":"4"}},{"id":3607843,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-06T21:06:28.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in substantially equal monthly installments beginning on April 5, 2019 and continuing until March 5, 2023, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date."}],"balance_after":185000,"derivative":{"exercise_price":8.59,"expiration_date":"2029-03-05","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0000899243-19-006432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924319006432/doc4.xml","form_type":"4"}},{"id":3777870,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-01T20:05:43.000Z","date":"2018-10-31","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to one-fourth (1/4) of the shares on October 2, 2019, and the remainder will vest at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as President and Chief Executive Officer through each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":7.91,"expiration_date":"2028-10-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-027889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318027889/doc4.xml","form_type":"4"}},{"id":3808257,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to Purchase Common Stock","published_at":"2018-09-25T09:20:46.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2018, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock. The option will vest and become exercisable in three equal installments on each of September 21, 2019, September 21, 2020 and September 21, 2021."}],"balance_after":25000,"derivative":{"exercise_price":16.36,"expiration_date":"2028-09-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-18-058320","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465918058320/a4.xml","form_type":"4"}},{"id":3903041,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-06T21:20:22.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in substantially equal monthly installments beginning on July 5, 2018 and continuing until June 5, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Interim President and Chief Executive Officer through each such vesting date."}],"balance_after":54000,"derivative":{"exercise_price":9.55,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0000899243-18-015255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318015255/doc4.xml","form_type":"4"}},{"id":3994239,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":34400,"kind":"person","name":"Brennan Aoife","position":1,"cik":"0001714563","reported_name":"Brennan Aoife","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-15T20:05:28.000Z","date":"2018-03-14","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date."}],"balance_after":56000,"derivative":{"exercise_price":9.95,"expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0000899243-18-007530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318007530/doc4.xml","form_type":"4"}}]}